X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

FDA authorizes monoclonal antibodies for treatment of COVID-19

Content Team by Content Team
26th November 2020
in FDA Approvals, News
FDA authorizes monoclonal antibodies for treatment of COVID-19

FDA issued an EUA for casirivimab and imdevimab (Regeneron Pharmaceuticals) to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years or older weighing about 88 pounds with positive results of direct SARS-CoV-2 viral testing and who are at high risk for pr

FDA issued an emergency use authorization (EUA) for casirivimab and imdevimab (Regeneron Pharmaceuticals) to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years or older weighing about 88 pounds with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. A clinical trial of patients with COVID-19 found that administering casirivimab and imdevimab together reduced COVID-19-related hospitalizations or emergency department visits in patients at high risk for disease progression within 28 days after treatment when compared with placebo. The safety and effectiveness of this treatment for use against COVID-19 continues to be evaluated. Casirivimab and imdevimab must be administered together by I.V. infusion. The drugs are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

“The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic,” said Patrizia Cavazzoni, MD, acting director of FDA’s Center for Drug Evaluation and Research. “We will continue to facilitate the development, evaluation and availability of COVID-19 therapies.” Under the EUA, fact sheets that provide key information about using casirivimab and imdevimab administered together in treating COVID-19 as authorized must be made available to health care providers and to patients and caregivers. These fact sheets include dosing instructions, potential side effects and drug interactions.

 

Previous Post

AstraZeneca says AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Next Post

China likely to approve a COVID-19 vaccine by year end to meet the need of epidemic-stricken countries

Related Posts

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Takeda
News

AstraZeneca and J&J COVID-19 Shots Crucial To Meet US Vaccination Goal

14th December 2020
Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine
News

Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

14th December 2020
U.S. FDA confirms Pfizer COVID vaccine safe & effective
FDA Approvals

U.S. FDA confirms Pfizer COVID vaccine safe & effective

9th December 2020
Abzena Invests $60M Into cGMP Manufacturing Capacity
Drug Development

COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

9th December 2020
Next Post
China likely to approve a COVID-19 vaccine by year end to meet the need of epidemic-stricken countries

China likely to approve a COVID-19 vaccine by year end to meet the need of epidemic-stricken countries

Latest News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In